Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis

Brain

Volumn 131, Issue 4, 2008, Pages 1123-1133

  Chen, John W ^a,b   Breckwoldt, Michael O ^a   Aikawa, Elena ^a   Chiang, Gloria ^a   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b 5404 Building 149 ^*  (United States)

Author keywords

Demyelination; MRI; Myeloperoxidase; Neuroinflammation; Targeted imaging

Indexed keywords

MYELOPEROXIDASE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; IMAGING; INFLAMMATION; INFLAMMATORY CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BIOLOGICAL MARKERS; CEREBELLUM; CLINICAL ENZYME TESTS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MICROGLIA; MICROSCOPY, CONFOCAL; MULTIPLE SCLEROSIS; PEROXIDASE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 41849109453     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn004     Document Type: Article

References (46)

1. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001; 108: 1759-70.
2. Berger C, Hiestand P, Kindler-Baumann D, Rudin M, Rausch M. Analysis of lesion development during acute inflammation and remission in a rat model of experimental autoimmune encephalomyelitis by visualization of macrophage infiltration, demyelination and blood-brain barrier damage. NMR Biomed 2006; 19: 101-7.
3. Bradley PP, Christensen RD, Rothstein G. Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 1982; 60: 618-22.
4. Brennan M, Gaur A, Pahuja A, Lusis AJ, Reynolds WF. Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 112: 97-105.
5. Brochet B, Deloire MS, Touil T, Anne O, Caille JM, Dousset V, et al. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE. Neuroimage 2006; 32: 266-74.
6. Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005; 252 (Suppl 5): v3-9.
7. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
8. Chataway J, Sawcer S, Feakes R, Coraddu F, Broadley S, Jones HB, et al. A screen of candidates from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis. J Neuroimmunol 1999; 98: 208-13.
9. Chen JW, Querol Sans M, Bogdanov AA Jr, Weissleder R. Imaging myeloperoxidase in mice using novel amplifiable paramagnetic substrates. Radiology 2006; 240: 473-81.
10. Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003; 60: 640-6.
11. Dousset V, Ballarino L, Delalande C, Coussemacq M, Canioni P, Petry KG, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999; 20: 223-7.
12. Dousset V, Brochet B, Deloire MS, Lagoarde L, Barroso B, Caille JM, et al. MR imaging of relapsing multiple sclerosis patients using ultra-smallparticle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 2006; 27: 1000-5.
13. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996; 46: 379-84.
14. Floris S, Blezer EL, Schreibelt G, Dopp E, van der Pol SM, Schadee-Eestermans IL, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 2004; 127: 616-27.
15. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 602-11.
16. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-55.
17. Giovannoni G, Silver NC, Good CD, Miller DH, Thompson EJ. Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis. Eur Neurol 2000; 44: 222-8.
18. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
19. Greer JM, Sobel RA, Sette A, Southwood S, Lees MB, Kuchroo VK. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J Immunol 1996; 156: 371-9.
20. Heinecke JW. Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors 1997; 6: 145-55.
21. Heinecke JW. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 1999; 133: 321-5.
22. Imitola J, Chitnis T, Khoury SJ. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 2006; 63: 25-33.
23. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
24. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999; 122 (Pt 1): 17-26.
25. Klebanoff SJ. A peroxidase-mediated antimicrobial system in leukocytes. J Clin Invest 1967; 46: 1078-85.
26. Klebanoff SJ. Myeloperoxidase: contribution to the microbicidal activity of intact leukocytes. Science 1970; 169: 1095-7.
27. Klebanoff SJ, Waltersdorph AM, Rosen H. Antimicrobial activity of myeloperoxidase. Methods Enzymol 1984; 105: 399-403.
28. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-12.
29. MacKenzie-Graham A, Tinsley MR, Shah KP, Aguilar C, Strickland LV, Boline J, et al. Cerebellar cortical atrophy in experimental autoimmune encephalomyelitis. Neuroimage 2006; 32: 1016-23.
30. Merkler D, Boscke R, Schmelting B, Czeh B, Fuchs E, Bruck W, et al. Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol 2006; 16: 117-23.
31. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4: 281-8.
32. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-12.
33. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997; 78: 97-107.
34. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
35. Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM. Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005; 128: 2713-21.
36. Querol M, Chen JW, Weissleder R, Bogdanov A Jr. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org Lett 2005; 7: 1719-22.
37. Querol Sans M, Chen JW, Bogdanov AA Jr. A paramagnetic contrast agent with myeloperoxidase-sensing properties. Org Biomol Chem 2006; 4: 1887-95.
38. Querol Sans M, Chen JW, Weissleder R, Bogdanov AA Jr. Myeloperoxidase activity imaging using (67)Ga labeled substrate. Mol Imaging Biol 2005; 7: 403-10.
39. Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003; 50: 309-14.
40. Rausch PG, Moore TG. Granule enzymes of polymorphonuclear neutrophils: a phylogenetic comparison. Blood 1975; 46: 913-9.
41. Seeldrayers PA, Syha J, Morrissey SP, Stodal H, Vass K, Jung S, et al. Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis. J Neuroimmunol 1993; 46: 199-206.
42. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-92.
43. Storch MK, Bauer J, Linington C, Olsson T, Weissert R, Lassmann H. Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatability complex (MHC) haplotype-related. J Neuropathol Exp Neurol 2006; 65: 1137-42.
44. Tiruppathi C, Naqvi T, Wu Y, Vogel SM, Minshall RD, Malik AB. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci U S A 2004; 101: 7699-704.
45. Xu S, Jordan EK, Brocke S, Bulte JWM, Quigley L, Tresser N, et al. Study of relapsing remitting experimental allergic encephalomyelitis SJL Mouse Model using MION-46L enhanced in vivo MRI: early histopathological correlation. J Neurosci Res 1998; 52: 549-58.
46. Zakrzewska-Pniewska B, Styczynska M, Podlecka A, Samocka R, Peplonska B, Barcikowska M, et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004; 10: 266-71.